Mazdutide has substantial human trial evidence and is approved in China for specific uses. That approval is jurisdiction-specific and does not make other products, indications or countries equivalent.
Still uncertain: Global regulatory approval, long-term outcomes across diverse populations, and equivalence of non-authorised products are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea
Human evidence
Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.
Regulatory status
First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine.
Main limitations
Global regulatory approval, long-term outcomes across diverse populations, and equivalence of non-authorised products are not established.
Safety
GI adverse events are the main recurring trial signal; longer-term outcomes and use outside studied populations require caution.
Evidence reviewed
2026-09-18
i
Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Randomized Phase 3 human evidence + China approval
Context: Chinese adults with overweight/obesity
Finding: Substantial Phase 3 weight-loss efficacy in Chinese populations.
Uncertainty / evidence gap: No direct completed head-to-head obesity-outcome trial against current high-dose semaglutide/tirzepatide in the retrieved evidence.
GI adverse events are the main recurring trial signal; longer-term outcomes and use outside studied populations require caution.
Gastrointestinal adverse events including diarrhoea, nausea and vomiting are common in trials; longer-term and broader-population safety continues to accumulate.
Technical details
Mechanism / biologyCo-agonism at glucagon and GLP-1 receptors aims to combine appetite/glycaemic effects with glucagon-linked energy expenditure and hepatic metabolic effects.
Route / formulation boundaryClinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent.
Identity / data-quality noteClearly distinguish China authorisation from status in UK/EU/US.
Study / label regimen evidencePhase 3 human dosing verified. GLORY-1 studied 4 mg and 6 mg once weekly; GLORY-2 studied 9 mg once weekly. See dosing records.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
1outcome records
5linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
